NCT05997056已完成2 期
A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 8
- 主要终点
- Efficacy of nab-sirolimus
研究概览
简要总结
A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors
详细描述
This is a prospective phase 2 single arm, open-label, multi-institutional study to determine the efficacy and safety prospective of nab-sirolimus and patients with functional or non-functional, well-differentiated, locally advanced unresectable in metastatic NETs of the GI tract, lung, or pancreas.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with functional or non-functional, well-differentiated, locally advanced unresectable or metastatic NETs of the GI tract, lung, or pancreas who have received 2 or less prior lines of therapy excluding somatostatin analogs
- •Patients with functional NETs may enroll if:
- •the patient has been on a stable dose of an somatostatin analogs for ≥12 weeks and
- •the patient has experienced disease progression while on stable somatostatin analogs dose
- •Patients must have 1 or more measurable target lesions by RECIST v1.1
- •Age: 18 years or older
- •Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 or Karnofsky Performance Status (KPS) ≥80
- •Adequate liver function:
- •Total bilirubin ≤1.5 × upper limit of normal (ULN) (unless due to Gilbert's syndrome or attributable to liver metastases, then ≤3 × ULN)
- •Aspartate aminotransferase (AST) and alanine transaminase (ALT) ≤2.5 × ULN (≤5 × ULN if attributable to liver metastases)
- •Adequate renal function: creatinine clearance ≥30 mL/min, Cockcroft-Gault creatinine clearance = ((140-age) × weight[kg]) / (72 × serum creatinine [mL/min]) × 0.85, if female.
- •Adequate hematologic parameters:
- •Absolute neutrophil count (ANC) ≥1.0 × 10^9/L (growth factor support allowed)
- •Platelet count ≥100,000/mm^3 (100 × 10^9/L) (transfusion and/or growth factor support allowed)
- •Hemoglobin ≥8.0 g/dL (transfusion and/or growth factor support allowed)
- •Fasting serum triglyceride must be ≤300 mg/dL; fasting serum cholesterol must be less than or equal to 350 mg/dL
- •Minimum of 4 weeks since any major surgery, completion of radiation, and adequately recovered from the acute toxicities of any prior therapy, including neuropathy, to Grade ≤1
- •Male or non-pregnant and non-breastfeeding female:
- •Females of childbearing potential must agree to use effective contraception or abstinence without interruption from 28 days prior to starting study medication throughout 3 months after last dose of study medication and have a negative serum pregnancy test (beta human chorionic gonadotropin [β-hCG]) result at screening and agree to ongoing pregnancy testing during the course of the study, and after the EOS treatment. A second form of birth control is required even if she has had a tubal ligation.
- •Male patients must agree not to donate sperm and must practice abstinence or agree to use a condom during sexual contact with a pregnant female or a female of childbearing potential while participating in the study and throughout 3 months after last dose of study medication. A second form of birth control is required even if he has undergone a successful vasectomy.
- •Sexual abstinence is considered a highly effective contraceptive method only if defined as refraining from heterosexual intercourse from 28 days prior to starting study medication throughout 3 months after last dose of study medication. The reliability of sexual abstinence should be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the patient.
- •The patient or the patient's legal guardian(s) understand(s) and sign(s) the informed consent
- •Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures
- •Patients with a known history of human immunodeficiency virus (HIV) infection are eligible if:
- •There has been no acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection in 12 months prior to enrollment.
- •The patient has been receiving an antiretroviral therapy regimen for ≥4 weeks and the HIV viral load is <400 copies/mL prior to enrollment.
- •Antiretroviral therapy regimen does not include strong cytochrome (CYP)3A4 inhibitors or inducers
排除标准
- •Prior treatment with mTOR inhibitors including nab-sirolimus
- •Note: Patients who have previously received locoregional or liver-directed therapies (radiofrequency or microwave ablation, transarterial chemoembolization, etc.) are eligible to enroll in the study.
- •Patients with functional NETs who are experiencing uncontrolled symptoms attributed to hormones and other vasoactive substances secreted by the tumor
- •Patients with inactivating TSC1 or TSC2 alterations (based on tissue or liquid NGS)
- •Severe (Grade ≥3) ongoing infection requiring parenteral or oral anti-infective treatment, either ongoing or completed ≤7 days prior to enrollment
- •Patients who have any severe and/or uncontrolled medical or psychiatric conditions or other conditions that could affect their participation including:
- •Known or suspected brain metastases
- •Severe heart disease defined as unstable angina pectoris, NYHA Class III or IV congestive heart failure, myocardial infarction ≤6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.
- •Severe lung disease defined as a diffusing capacity for carbon monoxide that is ≤50% of normal predicted value and/or an O2 saturation ≤88% at rest on room air
- •(Note: Spirometry and pulmonary function tests are not required to be performed unless clinically indicated.)
- •Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy
- •A history of malignancies other than the one under treatment unless the patient is disease-free for more than 5 years from diagnosis. Controlled non-melanoma skin cancers, carcinoma in situ of the cervix, resected incidental prostate cancer, certain low-grade hematologic malignancies (eg, chronic lymphocytic leukemia, follicular lymphoma, etc), or other adequately treated carcinoma in situ may be eligible, after discussion with the medical monitor.
- •Uncontrolled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg)
- •Patients with history of interstitial lung disease and/or pneumonitis, or pulmonary hypertension
- •Active Hepatitis B and/or Hepatitis C infection and detectable viral load despite antiviral therapy.
- •Required use of concomitant medications with strong CYP3A4 interactions (induction or inhibition) should be discontinued (strong inhibitors include ketoconazole, itraconazole, voriconazole, erythromycin, clarithromycin, telithromycin; strong inducers include rifampin and rifabutin). These agents must be discontinued prior to first dose of nab-sirolimus.
研究组 & 干预措施
neuroendocrine tumors
Experimental
Patients with well-differentiated neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas.
干预措施: nab-sirolimus (Drug)
结局指标
主要结局
Efficacy of nab-sirolimus
时间窗: 12 Months
Objective Response Rate (ORR), defined as the proportion of patients with best overall response (BOR) of confirmed partial response (PR) or complete response (CR) from the time of study treatment initiation until progression of disease (PD) as determined by the Investigator using RECIST v1.1
Percentage of Participants With Objective Response Rate
时间窗: From the start of study treatment to radiographically confirmed disease progression (PD) per RECIST v1.1, assessed at screening, every 6 weeks (±7 days) for the first 12 weeks, and every 12 weeks (±7 days) thereafter, up to 22 months.
Objective Response Rate (ORR) is defined as the proportion of patients with best overall response (BOR) of confirmed partial response (PR) or complete response (CR) from the time of study treatment initiation until progression of disease (PD) as determined by the Investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Progression (PD) is defined per RECIST v1.1 as at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or the appearance of one or more new lesions.
次要结局
- Time to response(12 Months)
- Progression-free survival(12 Months)
- Duration of response(12 Months)
- Disease control rate(12 Months)
- Overall survival(24 Months)
- Incidence and severity of treatment(12 Months)
- Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events.(From first dose of study treatment through end of treatment (estimated up to 18 months) plus safety follow-up of 30 days after the last dose.)
- Duration of Response (DOR)(From first documented response (CR or PR) to radiographically confirmed disease progression (PD) per RECIST v1.1 or death from any cause, assessed at screening, every 6 weeks for the first 12 weeks, and every 12 weeks thereafter, up to 22 months)
- Disease Control Rate (DCR)(From the start of study treatment to radiographically confirmed disease progression (PD) per RECIST v1.1, assessed at screening, every 6 weeks for the first 12 weeks, and every 12 weeks thereafter, up to 22 months)
- Time to Response (TTR)(From the first dose of study treatment to the initial documentation of complete response (CR) or partial response (PR) per RECIST v1.1 , assessed at screening, every 6 weeks for the first 12 weeks, and every 12 weeks thereafter, up to 22 months)
- Progression-free Survival（PFS）(From first dose of study treatment until the date of first documented disease progression or death from any cause, whichever occurs first, assessed every 6 weeks for the first 12 weeks and every 12 weeks thereafter, up to approximately 21 months)
- Overall Survival（OS）(From first dose of study treatment until the date of death from any cause, assessed approximately every 12 weeks following the end-of-treatment visit, up to approximately 24 months.)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
2 期
A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComaMalignant PEComaNCT02494570Aadi Bioscience, Inc.34
进行中（未招募）
2 期
Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)Tumor, SolidMetastasisMetastatic CancerCancer MetastaticTumorsNeoplasmsNeoplasm MetastasisSolid TumorAdvanced Solid TumorAdvanced CancerMalignant Solid TumorMalignant Solid NeoplasmMalignant NeoplasmMalignant TumorCancerTSC1TSC2Metastatic Solid TumorMetastatic NeoplasmTumorTSCNCT05103358Aadi Bioscience, Inc.120
招募中
2 期
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial CancerEndometrial CancerEndometrioid TumorRecurrent Endometrial CarcinomaEndometrioid Endometrial CancerCancerTumorNCT05997017Aadi Bioscience, Inc.29
进行中（未招募）
2 期
Nab-Sirolimus and Endocrine Therapy in Recurrent Low Grade Serous Ovarian Cancer (NARETO)Low Grade Ovarian Serous AdenocarcinomaNCT06494150University of Oklahoma37
已完成
1 期
Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal CancerColorectal Cancer MetastaticNCT03439462Aadi Bioscience, Inc.60